

OIPE
 SEP 10 2001
 PATENT & TRADEMARK
 15733

RECEIVED
 SEP 17 2001
 TECH CENTER 1600/2900

| | | | | | |
|--|---|----|---|--------------------------|------------------------------|
| SUBSTITUTE for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/815,597 |
| | | | | Filing Date | March 23, 2001 |
| | | | | First Named Inventor | Wolin |
| | | | | Group Art Unit | 1632 1642 |
| | | | | Examiner Name | Not yet assigned A.M. Harris |
| Sheet | 1 | of | 1 | Attorney Docket Number | PP01658.002 (035784/209107) |

| U. S. PATENT DOCUMENTS | | | | | | |
|------------------------|-----------------------|-----------------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant Of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|----------|-------------------------|----------|-----------------------------------|---|--|---|----------------|
| Examiner Initials | Cite No. | Foreign Patent Document | | Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| SM | 1 | WO | 00/09160 | A1 | IDEC Pharmaceuticals Corporation | 02-24-2000 | Whole Document | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|---|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| STAP | 2 | JANAKIRAMAN <i>et al.</i> (1998) "Rituximab: Correlation Between Effector Cells and Clinical Activity in NHL," <i>Blood</i> 10: 337a. | |
| SM | 3 | KEILHOLZ <i>et al.</i> (1999) "Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease After Administration of Rituximab (Anti CD 20 Monoclonal Antibody) and Interleukin-2," <i>Leukemia and Lymphoma</i> 35: 641-642. | |
| SM | 4 | LEGET <i>et al.</i> (1998) "Use of Rituximab, The New FDA-Approved Anti-body," <i>Current Opinion on Oncology</i> 10: 548-551. | |
| SM | 5 | MALONEY <i>et al.</i> (1998) "Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies," <i>Oncology</i> 12: 63-76. | |
| SM | 6 | MALONEY <i>et al.</i> (1994) "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2BB) in Patients with Recurrent B-Cell Lymphoma," <i>Blood</i> 84: 2457-2466. | |
| SM | 7 | YIRINEC <i>et al.</i> (1999) "Preliminary Report on Biological Effects of Rituxan (R) and Interleukin-2 (IL-2) in Patients with Low-Grade or Mantle Cell Non-Hodgkins Lymphoma (NHL)," <i>Blood</i> 94: 270b. | |
| | | | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 9/30/03 |
|--------------------|--------------------|-----------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.
² See attached Kinds of U.S. Patent Documents.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------------|
| Application Number | 09/815,597 |
| Filing Date | March 23, 2001 |
| First Named Inventor | Wolin |
| Group Art Unit | 1632-1642 |
| Examiner Name | Not yet assigned A.M. Harris |
| Attorney Docket Number | PP01658.002 (035784/209107) |

Sheet 1 of 1

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant Of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
|--------------------|-----------------------|-----------------------------|-----------------------------------|---|--|---|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document Office ³ | Number ⁴ | Kind Code (if known) ⁵ | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-------------------|----------|---|---------------------|-----------------------------------|---|--|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|-------------------|----------|---|---|
| SM | 45 | HOOIJBERG, E., <i>et al.</i> , "Enhanced Antitumor Effects of CD20 over CD19 Monoclonal Antibodies in a Nude Mouse Xenograft Model," <i>Cancer Research</i> , February 15, 1995, pp. 840-846, Vol. 55(4), American Association for Cancer Research, Inc., USA. | |
| SM | 46 | HOOIJBERG, E., <i>et al.</i> , "Eradication of Large Human B Cell Tumors in Nude Mice with Unconjugated CD20 Monoclonal Antibodies and Interleukin 2," <i>Cancer Research</i> , June 15, 1995, pp. 2627-2634, Vol. 55(12), American Association for Cancer Research, Inc., USA. | |
| | | | |
| | | | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 9/30/03 |
|--------------------|--------------------|-----------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2107910v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

| | | | |
|---|------------------------|--------------------------|---------------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/815,597 |
| | | Filing Date | March 23, 2001 |
| | | First Named Inventor | Wolin |
| | | Group Art Unit | 1632 1642 |
| | | Examiner Name | Not yet assigned Alana M. Hanks |
| Sheet ONE of 3 | Attorney Docket Number | | PP01658.002 (035784/209107) |


| U. S. PATENT DOCUMENTS | | | | | | |
|------------------------|-------------|----------------------|-------------------------|--|--|---|
| Examiner Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant Of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
| | | Number | Kind Code (if known) | | | |
| SSH | 8 | 4,816,567 | | Cabilly <i>et al.</i> | 03-28-1989 | |
| SSH | 9 | 4,946,778 | | Ladner <i>et al.</i> | 08-07-1990 | |
| SSH | 10 | 5,260,203 | | Ladner <i>et al.</i> | 11-09-1993 | |
| SSH | 11 | 5,425,940 | | Zimmerman <i>et al.</i> | 06-20-1995 | |
| SSH | 12 | 5,455,030 | | Ladner <i>et al.</i> | 10-03-1995 | |
| SSH | 13 | 5,736,137 | | Anderson <i>et al.</i> | 04-07-1998 | |
| SSH | 14 | 5,750,105 | | Newman <i>et al.</i> | 05-12-1998 | |
| SSH | 15 | 5,756,096 | | Newman <i>et al.</i> | 05-26-1998 | |
| SSH | 16 | 5,776,456 | | Anderson <i>et al.</i> | 07-07-1998 | |
| SSH | 17 | 5,843,439 | | Anderson <i>et al.</i> | 12-01-1998 | |
| SSH | 18 | 5,856,456 | | Whitlow <i>et al.</i> | 01-05-1999 | |
| SSH | 19 | 5,939,598 | | Kucherlapati <i>et al.</i> | 08-17-1999 | |
| SSH | 20 | 6,015,542 | | Kaminski <i>et al.</i> | 01-18-2000 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-------------|-------------------------|----------|-------------------------|--|--|--|---|
| Examiner Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
| | | Office | Number | Kind Code (if known) | | | | |
| SSH | 21 | WO | 94/11026 | | IDEC Pharmaceuticals Corporation | 05-26-1994 | | |
| SSH | 22 | WO | 98/56418 | | Genentech, Inc. | 12-17-1998 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | | | |
|-----------------------|--------------------|--------------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 9/30/03 |
|-----------------------|--------------------|--------------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|---|--------|--------------------------|------------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/815,597 |
| | | Filing Date | March 23, 2001 |
| | | First Named Inventor | Wolin |
| | | Group Art Unit | 1632 1642 |
| | | Examiner Name | Not yet assigned A.M. HARRIS |
| Sheet | 3 of 3 | Attorney Docket Number | PP01658.002 (035784/209107) |



RECEIVED
JAN 11 2002
TECH CENTER 8903/2900

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|--|---|
| Examiner Initials | Cite No. | Invention name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| SJM | 23 | ALLISON, M.K., et al., "Phase II Trial of Outpatient Interleukin-2 in Malignant Lymphoma, Chronic Lymphocytic Leukemia, and Selected Solid Tumors," <i>Journal of Clinical Oncology</i> , January 1989, pp. 75-80, Vol. 7 (1). | |
| SJM | 24 | BERNSTEIN, Z.P., et al., "Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus - Associated Malignancy Results in Selective Expansion of Innate Immune Effectors without Significant Clinical Toxicity," <i>Blood</i> , November 1, 1995, pp. 3287-3294, Vol. 86 (9), The American Society of Hematology, USA. | |
| SJM | 25 | BERNSTEIN, Z.P., et al., "Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkin's Lymphoma and Hodgkin's Disease," <i>Journal of Immunotherapy</i> , 1991, pp.141-146, Vol. 10(2), 1991 Raven Press, Ltd., New York, USA. | |
| SJM | 26 | CARON, P.C., et al., "Interleukin-2 Enhancement of Cytotoxicity by Humanized Monoclonal Antibody M195 (Anti-CD33) in Myelogenous Leukemia," <i>Clinical Cancer Research</i> , January 1995, pp. 63-70, Vol. 1. | |
| SJM | 27 | CARSON, W.E., et al., "CD56 ^{bright} Natural Killer Cell Subsets: Characterization of Distinct Functional Responses to Interleukin-2 and the C-kit Ligand," <i>European Journal of Immunology</i> , 1997 pp. 354-360, Vol. 27, VCH Verlagsgesellschaft mbH, D-69451 Weinheim. | |
| SJM | 28 | COIFFIER, B., et al., "Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study," <i>Blood</i> , September 15, 1998, pp. 1927-1932, Vol. 92(6), The American Society of Hematology, USA. | |
| SJM | 29 | DAVIS, T.A., et al., "Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression," <i>Clinical Cancer Research</i> , March 1999, pp. 611-615, Vol. 5. | |
| SJM | 30 | DUGGAN, D.B., et al., "A Phase II Study of Recombinant Interleukin-2 With or Without Recombinant Interferon- β in Non-Hodgkin's Lymphoma. A Study of the Cancer and Leukemia Group B," <i>Journal of Immunotherapy</i> , November 2, 1992, pp. 115-122, Vol. 12(2), 1992 Raven Press, Ltd., New York, USA. | |
| SJM | 31 | FROST, J.D., et al., "A Phase I/II Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 in Children with Refractory Neuroblastoma," <i>Cancer</i> , July 15, 1997, pp. 317-333, Vol. 80(2), American Cancer Society, USA. | |
| SJM | 32 | GISSELBRECHT, C., et al., "Interleukin-2 Treatment in Lymphoma: A Phase II Multicenter Study," <i>Blood</i> , April 15, 1994, pp. 2081-2085, Vol. 83(8), The American Society of Hematology, USA. | |
| SJM | 33 | HANK, J.A., et al., "Treatment of Neuroblastoma Patients with Antiganglioside GD ₂ Antibody plus Interleukin-2 Induces Antibody-Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro," <i>Journal of Immunotherapy</i> , 1994, pp. 29-37, Vol. 15(1), 1994 Raven Press, Ltd., New York, USA. | |
| SJM | 34 | KHATRI, V.P., et al., "Ultra Low Dose Interleukin-2 Therapy Promotes a Type 1 Cytokine Profile In Vivo in Patients with AIDS and AIDS-Associated Malignancies," <i>Journal of Clinical Investigation</i> , March 1998, pp. 1373-1378, Vol 101(6), The American Society for Clinical Investigation, Inc., USA. | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 9/30/03 |
|--------------------|--------------------|-----------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|---|------------------------|-----------------------------|----------------------------|
| Substitute for form 1449A/PTO | | Complete if known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/815,597 |
| | | Filing Date | March 23, 2001 |
| | | First Named Inventor | Wolin |
| | | Group Art Unit | 1632 1642 |
| | | Examiner Name | Not yet assigned A.M. Harf |
| Sheet 3 of 3 | Attorney Docket Number | PP01658.002 (035784/209107) | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----|---|---|
| Examiner Initials | No. | Incl. name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| SSM | 35 | MALONEY, D.G., et al., "IDEC-C2-B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," <i>Blood</i> , September 15, 1997, pp. 2188-2195, Vol. 90(6), The American Society of Hematology, USA. | |
| SSM | 36 | MALONEY, D.G., et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> , October 1997, pp. 3266-3274, Vol. 15(10), American Society of Clinical Oncology, USA. | |
| SSM | 37 | MCLAUGHLIN, P., et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," <i>Journal of Clinical Oncology</i> , August 1998, pp. 2825-2833, Vol. 16(8), American Society of Clinical Oncology, USA. | |
| SSM | 38 | NAGLER, A., et al., "Immunotherapy with Recombinant Human Interleukin-2 and Recombinant Interferon- α in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation," <i>Blood</i> , June 1, 1997, pp. 3951-3959, Vol. 89(11), The American Society of Hematology, USA. | |
| SSM | 39 | PARKINSON, D.R., et al., "Biologic Therapies for Low-Grade Lymphomas," <i>Seminars in Oncology</i> , October 1993, pp. 111-117, Vol. 20(5), Suppl. 5. | |
| SSM | 40 | SHAN, D., et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 with Monoclonal Antibodies," <i>Blood</i> , March 1, 1998, pp. 1644-1652, Vol. 91(5), The American Society of Hematology, USA. | |
| SSM | 41 | SZNOL, M., and D.R. Parkinson, "Interleukin-2 in Therapy of Hematologic Malignancies," <i>Blood</i> , April 15, 1994, pp. 2020-2022, Vol. 83(8), The American Society of Hematology, USA. | |
| SSM | 42 | VAN BESSEN, K., et al., "Activity of Interleukin-2 in Non-Hodgkin's Lymphoma Following Transplantation of Interleukin-2-Activated Autologous Bone Marrow or Stem Cells," <i>The Cancer Journal from Scientific American</i> , 1997, pp. 130-132, Vol. 3(1), Suppl. 1, Scientific American. | |
| SSM | 43 | VLASVELD, L.T., et al., "Treatment of Low-Grade Non-Hodgkin's Lymphoma with Continuous Infusion of Low-Dose Recombinant Interleukin-2 in Combination with the B-Cell-Specific Monoclonal Antibody CLB-CD19," <i>Cancer Immunology Immunotherapy</i> , 1995, pp. 37-47, Vol. 40. | |
| SSM | 44 | WEBER, J.S., et al., "The Use of Interleukin-2 and Lymphokine-Activated Killer Cells for the Treatment of Patients with Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> , January 1992, pp. 33-40, Vol. 10(1). | |
| | | | |
| | | | |

| | | | |
|-----------------------|------------|--------------------|---------|
| Examiner Signature | <i>SSM</i> | Date Considered | 9/30/03 |
|-----------------------|------------|--------------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.